Johnson & Johnson, a global pharmaceutical corporation, has announced a significant acquisition. Laminar, a privately owned provider of medical technology, will be taken over by the company for a prepayment of $400 million. Johnson & Johnson announced this on Thursday and simultaneously adjusted its goals for the current year. The company stated that additional expenses for research and development work will be incurred for the acquisition, leading to a burden on earnings per share.
The adjusted key figure, which is particularly of interest to analysts, is now expected to be between $9.90 and $9.96 per share, after a higher value was previously targeted. This includes a burden of $0.17 per share due to acquisition expenses. Additionally, management announced that in 2024, further burdens of $0.15 per share are expected to arise.
Johnson & Johnson also has the opportunity to receive additional milestone payments if certain regulatory stages or clinical investigations by Laminar are achieved. A clinical study for approval of the novel treatment device for patients with atrial fibrillation is scheduled to begin in early next year. The company will become part of the medical technology division of Biosense Webster, a global leader in the treatment of cardiac arrhythmias.
The stock price of Johnson & Johnson rose 1.59 percent to $154.53 on the New York Stock Exchange. The acquisition of Laminar is expected to have a positive impact on the company and strengthen its position as a leading provider in the medical technology industry.
The acquisition of Laminar is part of Johnson & Johnson's strategic growth plans. Through the acquisition of promising companies and technologies, the company aims to expand its portfolio and advance its expertise in medical treatment.
The acquisition of Laminar is another milestone in the success story of Johnson & Johnson and underscores the company's commitment to improving healthcare worldwide. With Laminar's advanced technology and Biosense Webster's established expertise, Johnson & Johnson has the opportunity to enhance the lives of millions of patients through innovative treatment methods.
